# MIRACLE-T2D Montelukast Intervention for Renal, Cardiovascular and Eye Health in Type 2 Diabetes

Study · id `cardio:ct-nct07685886` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07685886](<https://clinicaltrials.gov/study/NCT07685886>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07685886

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 110 participants.

## Technical summary

Registry record NCT07685886. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-01 (anticipated); primary completion 2031-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 110 participants (planned count; ClinicalTrials.gov record NCT07685886, source copy `cardio:ctgov-nct07685886-2026-07-06`, retrieved 2026-10-26)
- Planned start: 2026-09-01 (anticipated) (ClinicalTrials.gov record NCT07685886, source copy `cardio:ctgov-nct07685886-2026-07-06`, retrieved 2026-10-26)
- Primary completion: 2031-06-30 (anticipated) (ClinicalTrials.gov record NCT07685886, source copy `cardio:ctgov-nct07685886-2026-07-06`, retrieved 2026-10-26)
- Completion: 2031-08-31 (anticipated) (ClinicalTrials.gov record NCT07685886, source copy `cardio:ctgov-nct07685886-2026-07-06`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07685886, source copy `cardio:ctgov-nct07685886-2026-07-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07685886-2026-07-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: MIRACLE-T2D Montelukast Intervention for Renal, Cardiovascular and Eye Health in Type 2 Diabetes
- Acronym: MIRACLE-T2D
- Condition: Diabetes
- Condition: Kidney Disease
- Condition: Vascular Disease
- Condition: Retinopathy
- Intervention (Drug): Montelukast
- Intervention (Drug): Placebo
- Lead sponsor: University of Colorado, Denver
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: University of Colorado, Denver (`cardio:org-university-of-colorado-denver`)

## Provenance

Content hash: 6c8f49169d349d520e4aa6cedca5741b30dbf286d5e3316b44d42d9d9d471986
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
